Mersana Therapeutics Soars 6.18% on Positive Earnings

On May 19, 2025, Mersana Therapeutics' stock surged by 6.18% in pre-market trading, reflecting a significant uptick in investor interest and confidence in the company's prospects.

Leerink Partners analyst Jonathan Chang maintained a Buy rating on Mersana Therapeutics on May 16, setting a price target of $2.00. This endorsement underscores the analyst's optimism about the company's future performance and strategic positioning in the biopharmaceutical sector.

Several institutional investors have adjusted their holdings in Mersana Therapeutics. Price T Rowe Associates Inc. MD reduced its stake by 37.3% in the fourth quarter, while other investors such as Avanza Fonder AB, SG Americas Securities LLC, China Universal Asset Management Co. Ltd., Sei Investments Co., and Geode Capital Management LLC either increased their positions or initiated new ones. These moves indicate a mixed sentiment among institutional investors, with some showing confidence in the company's long-term potential while others may be taking profits or reallocating their portfolios.

Mersana Therapeutics reported its quarterly earnings on May 15, 2025, with an earnings per share (EPS) of ($0.19), beating the consensus estimate of ($0.21). However, the company's revenue of $2.75 million fell short of analyst estimates of $6.05 million. Despite the revenue shortfall, the positive EPS surprise suggests that the company is managing its costs effectively and may be on track to improve its financial performance in the future.

Analysts have provided a range of price targets and ratings for Mersana Therapeutics. Wedbush reaffirmed an "outperform" rating with a $3.00 price target, while Truist Financial increased its price target to $10.00 and maintained a "buy" rating. William Blair and Guggenheim also issued "outperform" and "buy" ratings, respectively, with price targets of $5.00. The consensus rating among analysts is "Buy," with an average price target of $5.20, indicating a generally positive outlook for the company's stock.